Avalo Therapeutics, Inc.
AVTX
$19.42
-$0.04-0.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -85.22% | -43.08% | 55.20% | -47.48% | -57.92% |
| Total Depreciation and Amortization | 0.00% | 6.25% | -72.88% | -55.97% | -0.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 155.75% | 517.97% | -104.68% | 172.74% | 138.43% |
| Change in Net Operating Assets | 904.26% | -713.07% | 115.36% | -131.71% | 201.92% |
| Cash from Operations | -12.98% | -24.18% | 12.95% | -43.68% | -20.44% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,393.57% | 962.27% | 118.11% | 81.29% | -- |
| Cash from Investing | -1,393.57% | 962.27% | 118.11% | 81.29% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19,946.46% | 89.56% | -92.00% | 35,825.00% | -- |
| Repurchase of Common Stock | 100.00% | -- | 100.00% | 99.80% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 29,221.59% | 103.64% | -95.22% | 3,163.75% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 554.47% | 182.57% | 26.87% | 81.56% | -774.69% |